



# InertSearch™ for LC

Inertsil® Applications

## Analysis of Valsartan and Hydrochlorothiazide

(Under the Condition of the draft for the Japanese Pharmacopoeia,  
Valsartan and Hydrochlorothiazide Tablets)

Data No. LB519-0812



### Conditions

**System** : GL7700 HPLC system  
**Column** : InertSustainSwift C18  
(5  $\mu$  m, 125 x 3.0 mm I.D.)  
**Column Cat. No.** : 5020-88250  
**Eluent** : A) CH<sub>3</sub>CN  
B) Buffer\*  
A/B = 20/80, v/v  
**Flow rate** : 0.9 mL/min  
**Col. Temp.** : 25 °C  
**Detection** : UV 225 nm (UV7750 UV Detector)  
**Injection Vol.** : 10  $\mu$  L  
**Sample** : Standard

\*Dissolve 14.68 g of Na<sub>2</sub>HPO<sub>4</sub> · 12H<sub>2</sub>O and  
3.81 g of KH<sub>2</sub>PO<sub>4</sub> in 1000 mL of water.

### Analyte:

1. Hydrochlorothiazide 7 mg/L  
2. Valsartan 30 mg/L

Theoretical plates (2) : 1,135 ( $\geq$  500)  
Symmetry factor (2) : (0.7  $\leq$ ) 1.04 ( $\leq$  1.5)  
RSD of the peak  
area of 2 (%) (n=6) : 0.06 ( $\leq$  1.0)

Theoretical plates (1) : 4,355 ( $\geq$  3,000)  
Symmetry factor (1) : 1.17 ( $\leq$  2.0)  
RSD of the peak  
area of 1 (%) (n=6) : 0.13 ( $\leq$  1.0)